[go: up one dir, main page]

JOP20200160A1 - محاليل معلقة مائية للمركبات المسمى تي ام سي 278 - Google Patents

محاليل معلقة مائية للمركبات المسمى تي ام سي 278

Info

Publication number
JOP20200160A1
JOP20200160A1 JOP/2020/0160A JOP20200160A JOP20200160A1 JO P20200160 A1 JOP20200160 A1 JO P20200160A1 JO P20200160 A JOP20200160 A JO P20200160A JO P20200160 A1 JOP20200160 A1 JO P20200160A1
Authority
JO
Jordan
Prior art keywords
tmc278
aqueous suspensions
pharmaceutical compositions
prophylaxis
nanoparticles
Prior art date
Application number
JOP/2020/0160A
Other languages
English (en)
Inventor
Laurent Bruno Schueller
Lieven Elvire Colette Baert
Remoortere Peter Jozef Maria Van
Marc Karel Jozef Francois
Willy Albert Maria Carlo Dries
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38833797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20200160(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of JOP20200160A1 publication Critical patent/JOP20200160A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق هذا الاختراع بتركيبات دوائية (pharmaceutical compositions) للإعطاء بالحقن في العضل أو تحت الجلد، تشمل جسيمات صغيرة أو نانونية (متناهية الصغر) من مركب NNRT1 المسمى TMC278, معلقة في مادة حاملة (carrier) مائية مقبولة دوائيا، وباستخدام هذه التركيبات الدوائية (pharmaceutical compositions) في المعالجة والوقاية من عدوى HIV.
JOP/2020/0160A 2006-06-23 2020-06-24 محاليل معلقة مائية للمركبات المسمى تي ام سي 278 JOP20200160A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06115938 2006-06-23

Publications (1)

Publication Number Publication Date
JOP20200160A1 true JOP20200160A1 (ar) 2022-10-30

Family

ID=38833797

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0160A JOP20200160A1 (ar) 2006-06-23 2020-06-24 محاليل معلقة مائية للمركبات المسمى تي ام سي 278

Country Status (33)

Country Link
US (4) US20090176813A1 (ar)
EP (2) EP2040671B1 (ar)
JP (1) JP5292288B2 (ar)
KR (1) KR101406879B1 (ar)
CN (1) CN101478950B (ar)
AP (1) AP2618A (ar)
AR (1) AR061620A1 (ar)
AU (1) AU2007262941B2 (ar)
BR (2) BRPI0713334B1 (ar)
CA (1) CA2654115C (ar)
CL (1) CL2007001847A1 (ar)
CY (1) CY1120564T1 (ar)
DK (2) DK2040671T3 (ar)
EA (1) EA021700B1 (ar)
ES (2) ES2989051T3 (ar)
FI (1) FI3366278T3 (ar)
HR (2) HRP20241265T3 (ar)
HU (2) HUE038797T2 (ar)
IL (1) IL195491A (ar)
JO (1) JOP20200160A1 (ar)
LT (2) LT2040671T (ar)
MX (1) MX2009000158A (ar)
NZ (1) NZ573291A (ar)
PE (1) PE20080210A1 (ar)
PL (2) PL3366278T3 (ar)
PT (2) PT3366278T (ar)
RS (2) RS65990B1 (ar)
SG (1) SG173315A1 (ar)
SI (2) SI3366278T1 (ar)
TW (1) TWI413521B (ar)
UA (1) UA97641C2 (ar)
UY (1) UY30431A1 (ar)
WO (1) WO2007147882A2 (ar)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
JP5754005B2 (ja) 2006-01-20 2015-07-22 ヤンセン・アールアンドデイ・アイルランド Ｔｃｍ２７８を用いるｈｉｖ−感染症の長期間処置
TWI494133B (zh) 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
EP2306980A2 (en) * 2008-06-30 2011-04-13 Tibotec Pharmaceuticals Powders for reconstitution
ES2607107T3 (es) * 2008-12-24 2017-03-29 Janssen Sciences Ireland Uc Dispositivos implantables para tratar el VIH
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
HRP20201241T1 (hr) * 2011-04-15 2020-11-27 Janssen Pharmaceutica N.V. Nanosuspenzije lijeka osušene zamrzavanjem
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
HK1209638A1 (en) 2012-12-14 2016-04-08 Glaxosmithkline Llc Pharmaceutical compositions
BR112017006005A2 (pt) 2014-09-26 2017-12-19 Glaxosmithkline Ip No 2 Ltd composição farmacêutica, e, método de prevenção ou tratamento de uma infecção por hiv.
US10369129B2 (en) * 2016-05-31 2019-08-06 Taimed Biologics, Inc. Long acting pharmaceutical composition of protease inhibitor
TWI678203B (zh) * 2016-05-31 2019-12-01 中裕新藥股份有限公司 蛋白酶抑制劑之長效醫藥組合物
CN109475563A (zh) * 2016-05-31 2019-03-15 中裕新药股份有限公司 蛋白酶抑制剂的长效医药组合物
CN110191704A (zh) 2016-10-24 2019-08-30 爱尔兰詹森科学公司 可分散组合物
AU2018298855B2 (en) * 2017-07-14 2024-07-18 Janssen Pharmaceutica Nv Long-acting formulations
CN113440529B (zh) * 2020-03-25 2023-11-14 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
MX2023000439A (es) 2020-07-09 2023-02-09 Janssen Pharmaceutica Nv Formulaciones a largo plazo.
JP2023532981A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型配合物
JP2023532982A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型配合物
KR20230110763A (ko) * 2020-11-17 2023-07-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 질환 또는 장애의 치료 또는 예방
TW202233192A (zh) 2020-11-17 2022-09-01 愛爾蘭商健生科學愛爾蘭無限公司 Hiv感染之治療或預防
KR20240095514A (ko) 2021-11-17 2024-06-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 용해도 평가
CN119403543A (zh) 2022-04-22 2025-02-07 爱尔兰詹森科学公司 液体组合物
CN119403545A (zh) 2022-04-22 2025-02-07 爱尔兰詹森科学公司 冷冻干燥的组合物
TW202408526A (zh) 2022-05-17 2024-03-01 愛爾蘭商健生科學愛爾蘭無限公司 治療或預防hiv感染(一)
TW202408527A (zh) 2022-05-17 2024-03-01 愛爾蘭商健生科學愛爾蘭無限公司 治療或預防hiv感染(二)
CA3268292A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv LONG-ACTING FORMULAS
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2025054693A1 (pt) * 2023-09-14 2025-03-20 Instituto Hercílio Randon Premix funcional de nanopartículas, processo para sua obtenção, processo para modificação de propriedades de materiais e material com propriedades modificadas

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4102124A (en) * 1976-07-12 1978-07-25 Swager William E Locking clevis or the like
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5046881A (en) * 1991-02-01 1991-09-10 Swager William E Lockable pin and clevis
US5114260A (en) * 1991-05-13 1992-05-19 Hart Judy L Clevis and screw pin type shackle with pin lock
US5272824A (en) * 1993-05-10 1993-12-28 Caterpillar Inc. Tooth assembly with leaf spring retainer
US5423138A (en) * 1994-04-04 1995-06-13 Caterpillar, Inc. Tip to adapter interface
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
EP1214059B1 (en) * 1999-09-21 2005-05-25 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US20030166509A1 (en) * 2001-11-20 2003-09-04 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery and methods of use thereof
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
KR20130030305A (ko) * 2004-11-16 2013-03-26 엘란 파마 인터내셔널 리미티드 주사가능한 나노입자형 올란자핀 제형
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
JP5754005B2 (ja) * 2006-01-20 2015-07-22 ヤンセン・アールアンドデイ・アイルランド Ｔｃｍ２７８を用いるｈｉｖ−感染症の長期間処置

Also Published As

Publication number Publication date
HRP20241265T3 (hr) 2024-12-06
US11389447B2 (en) 2022-07-19
CA2654115A1 (en) 2007-12-27
DK2040671T3 (en) 2018-05-07
BRPI0713334A2 (pt) 2012-03-06
HRP20180629T1 (hr) 2018-06-01
RS65990B1 (sr) 2024-10-31
JP5292288B2 (ja) 2013-09-18
HUE038797T2 (hu) 2018-11-28
SI3366278T1 (sl) 2024-12-31
WO2007147882A3 (en) 2008-06-19
ES2989051T3 (es) 2024-11-25
RS57111B1 (sr) 2018-06-29
ES2662068T3 (es) 2018-04-05
PL2040671T3 (pl) 2018-08-31
DK3366278T3 (da) 2024-09-23
MX2009000158A (es) 2009-01-23
TWI413521B (zh) 2013-11-01
IL195491A0 (en) 2009-09-01
KR101406879B1 (ko) 2014-06-13
WO2007147882A2 (en) 2007-12-27
EA021700B1 (ru) 2015-08-31
TW200817008A (en) 2008-04-16
UA97641C2 (en) 2012-03-12
HUE068406T2 (hu) 2024-12-28
EP2040671A2 (en) 2009-04-01
BR122020011487B1 (pt) 2024-02-20
US20150010637A1 (en) 2015-01-08
CN101478950B (zh) 2013-02-06
LT3366278T (lt) 2024-11-11
AR061620A1 (es) 2008-09-10
JP2009541271A (ja) 2009-11-26
EP3366278B1 (en) 2024-08-07
EP3366278A1 (en) 2018-08-29
EA200970047A1 (ru) 2009-04-28
CA2654115C (en) 2015-12-22
LT2040671T (lt) 2018-05-10
CY1120564T1 (el) 2019-07-10
AP2618A (en) 2013-03-18
CN101478950A (zh) 2009-07-08
AP2008004682A0 (en) 2008-12-31
UY30431A1 (es) 2008-01-31
PL3366278T3 (pl) 2024-10-28
CL2007001847A1 (es) 2008-02-08
US20220273653A1 (en) 2022-09-01
KR20090023703A (ko) 2009-03-05
IL195491A (en) 2014-11-30
FI3366278T3 (fi) 2024-09-25
NZ573291A (en) 2011-11-25
PE20080210A1 (es) 2008-04-11
AU2007262941B2 (en) 2013-11-21
PT3366278T (pt) 2024-10-21
SG173315A1 (en) 2011-08-29
BRPI0713334A8 (pt) 2018-01-02
BRPI0713334B1 (pt) 2024-02-20
AU2007262941A1 (en) 2007-12-27
PT2040671T (pt) 2018-03-14
SI2040671T1 (en) 2018-05-31
US20090176813A1 (en) 2009-07-09
US20160089369A1 (en) 2016-03-31
EP2040671B1 (en) 2018-01-24

Similar Documents

Publication Publication Date Title
JOP20200160A1 (ar) محاليل معلقة مائية للمركبات المسمى تي ام سي 278
PH12020500076A1 (en) Long-acting formulations
JO2755B1 (ar) (استخدام 2-6-(3-امينو-بيبريدين-1-يل)-3-ميثيل-2 ,4-دايوكسو-3,4-دايهيدرو-2h- بيريميدين -1يل ميثيل -4- فلورو بينزونيتريل لمعالجة مرض السكر ,السرطان ,اضطرابات مناعه ذاتيه وعدوى hiv )
MY144318A (en) Methods of treating hiv infection.
MX2010002318A (es) Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
WO2009121063A3 (en) Chemokine receptor modulators
AP2007004095A0 (en) Cxcr4 antagonists for the treatment of hiv infection
NO20081592L (no) Dipeptidylpeptidaseinhibitorer for behandling av diabetes
WO2008067145A3 (en) Self-assembling peptide amphiphiles
PH12014500386A1 (en) Combination treatment for hepatitis c
WO2005089738A3 (en) Use and administration of bacterial efflux pump inhibitors
MX2009013835A (es) Forma de dosis estabilizada de picoplatino.
SA523440384B1 (ar) مركبات الفوسفوليبيدات واستخداماتها
WO2012168885A9 (en) Bisacodyl and its analogues as drugs for use in the treatment of cancer
TW200806295A (en) Long term treatment of HIV infection
TNSN07240A1 (en) Compounds for flaviviridae treatment
CL2007002671A1 (es) Compuestos derivados de octahidro-pirrolo[3,4-c]pirrol; composicion farmaceutica que la comprende; y uso del compuesto en el tratamiento del vih, sida o arc.
MX2023000439A (es) Formulaciones a largo plazo.
MX2022001261A (es) Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb.
GEP20257744B (en) Antimalarial agents
WO2006034001A3 (en) Methods of treating hiv infection
TW200709818A (en) Prevention of HIV-infection
EA201170004A1 (ru) Использование антагонистов h4-гистаминовых рецепторов для лечения послеоперационных спаек
MX2022001271A (es) Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.
ATE475408T1 (de) Formulierungen von tipifarnib zur intravenösen verabreichung